Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries. Bulk files are centralized on the Download page.
1,251-1,300 of 2,070
Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries.
2,069 ready
| Sample | Organ | Disease state | Cells | Dominant compartment ?Largest Tier 1 spatial domain by sample fraction; this is a biological neighborhood label, not a row-count summary. | Domain share | Purity | Diversity |
|---|---|---|---|---|---|---|---|
| NSCLC_38242124__IMC__86_B5,1 | Lung | Primary cancer | 3,182 | Tumor/Malignant | 67.1% | 0.99 | 0.05 |
| NSCLC_38242124__IMC__86_B5,10 | Lung | Primary cancer | 2,357 | Tumor/Malignant | 53.4% | 0.94 | 0.19 |
| NSCLC_38242124__IMC__86_B5,12 | Lung | Primary cancer | 137 | Tumor/Malignant | 52.6% | 0.47 | 0.89 |
| NSCLC_38242124__IMC__86_B5,13 | Lung | Primary cancer | 3,387 | Tumor/Malignant | 87.7% | 0.99 | 0.03 |
| NSCLC_38242124__IMC__86_B5,14 | Lung | Primary cancer | 2,142 | Tumor/Malignant | 30.1% | 0.91 | 0.28 |
| NSCLC_38242124__IMC__86_B5,2 | Lung | Primary cancer | 2,666 | Immune | 45.8% | 0.90 | 0.31 |
| NSCLC_38242124__IMC__86_B5,3 | Lung | Primary cancer | 3,885 | Immune | 29.1% | 0.90 | 0.29 |
| NSCLC_38242124__IMC__86_B5,4 | Lung | Primary cancer | 2,337 | Tumor/Malignant | 38.2% | 0.85 | 0.43 |
| NSCLC_38242124__IMC__86_B5,5 | Lung | Primary cancer | 2,876 | Tumor/Malignant | 50.6% | 0.95 | 0.13 |
| NSCLC_38242124__IMC__86_B5,6 | Lung | Primary cancer | 3,764 | Stromal | 68.7% | 0.96 | 0.11 |
| NSCLC_38242124__IMC__86_B5,7 | Lung | Primary cancer | 2,625 | Tumor/Malignant | 35.8% | 0.94 | 0.18 |
| NSCLC_38242124__IMC__86_B5,9 | Lung | Primary cancer | 190 | Immune | 53.2% | 0.74 | 0.48 |
| NSCLC_38242124__IMC__86_B6,1 | Lung | Primary cancer | 2,720 | Tumor/Malignant | 86.9% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__86_B6,10 | Lung | Primary cancer | 2,835 | Tumor/Malignant | 56.4% | 0.92 | 0.22 |
| NSCLC_38242124__IMC__86_B6,11 | Lung | Primary cancer | 2,424 | Stromal | 33.8% | 0.40 | 0.87 |
| NSCLC_38242124__IMC__86_B6,12 | Lung | Primary cancer | 19 | Tumor/Malignant | 52.6% | 0.80 | 0.55 |
| NSCLC_38242124__IMC__86_B6,13 | Lung | Primary cancer | 3,677 | Tumor/Malignant | 75.6% | 0.97 | 0.11 |
| NSCLC_38242124__IMC__86_B6,14 | Lung | Primary cancer | 1,447 | Stromal | 29.2% | 0.36 | 1.01 |
| NSCLC_38242124__IMC__86_B6,2 | Lung | Primary cancer | 3,223 | Tumor/Malignant | 57.1% | 0.96 | 0.13 |
| NSCLC_38242124__IMC__86_B6,3 | Lung | Primary cancer | 3,951 | Immune | 32.3% | 0.91 | 0.27 |
| NSCLC_38242124__IMC__86_B6,4 | Lung | Primary cancer | 918 | Stromal | 33.9% | 0.74 | 0.55 |
| NSCLC_38242124__IMC__86_B6,5 | Lung | Primary cancer | 1,799 | Tumor/Malignant | 50.4% | 0.98 | 0.09 |
| NSCLC_38242124__IMC__86_B6,6 | Lung | Primary cancer | 3,212 | Tumor/Malignant | 28.7% | 0.35 | 0.98 |
| NSCLC_38242124__IMC__86_B6,7 | Lung | Primary cancer | 2,833 | Tumor/Malignant | 57.4% | 0.97 | 0.12 |
| NSCLC_38242124__IMC__86_B6,8 | Lung | Primary cancer | 36 | Tumor/Malignant | 86.1% | 0.94 | 0.18 |
| NSCLC_38242124__IMC__86_B6,9 | Lung | Primary cancer | 1,140 | Stromal | 28.7% | 0.56 | 0.90 |
| NSCLC_38242124__IMC__86_B7,1 | Lung | Primary cancer | 2,196 | Tumor/Malignant | 48.0% | 0.95 | 0.19 |
| NSCLC_38242124__IMC__86_B7,10 | Lung | Primary cancer | 2,888 | Tumor/Malignant | 36.6% | 0.92 | 0.29 |
| NSCLC_38242124__IMC__86_B7,11 | Lung | Primary cancer | 51 | Other | 64.7% | 0.55 | 0.60 |
| NSCLC_38242124__IMC__86_B7,12 | Lung | Primary cancer | 4,398 | Immune | 35.7% | 0.92 | 0.25 |
| NSCLC_38242124__IMC__86_B7,14 | Lung | Primary cancer | 3,089 | Tumor/Malignant | 80.0% | 0.99 | 0.05 |
| NSCLC_38242124__IMC__86_B7,3 | Lung | Primary cancer | 1,944 | Stromal | 49.9% | 0.93 | 0.23 |
| NSCLC_38242124__IMC__86_B7,4 | Lung | Primary cancer | 1,886 | Tumor/Malignant | 52.8% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__86_B7,5 | Lung | Primary cancer | 1,768 | Tumor/Malignant | 27.8% | 0.92 | 0.28 |
| NSCLC_38242124__IMC__86_B7,6 | Lung | Primary cancer | 227 | Stromal | 70.9% | 0.49 | 0.78 |
| NSCLC_38242124__IMC__86_B7,7 | Lung | Primary cancer | 2,579 | Stromal | 34.0% | 0.32 | 1.03 |
| NSCLC_38242124__IMC__86_B7,8 | Lung | Primary cancer | 3,008 | Stromal | 38.5% | 0.90 | 0.27 |
| NSCLC_38242124__IMC__86_B7,9 | Lung | Primary cancer | 1,997 | Stromal | 28.2% | 0.72 | 0.65 |
| NSCLC_38242124__IMC__86_B8,1 | Lung | Primary cancer | 782 | Other | 29.4% | 0.75 | 0.59 |
| NSCLC_38242124__IMC__86_B8,10 | Lung | Primary cancer | 5,311 | Immune | 88.1% | 0.99 | 0.03 |
| NSCLC_38242124__IMC__86_B8,11 | Lung | Primary cancer | 1,030 | Stromal | 89.1% | 0.98 | 0.04 |
| NSCLC_38242124__IMC__86_B8,12 | Lung | Primary cancer | 4,337 | Tumor/Malignant | 39.5% | 0.94 | 0.20 |
| NSCLC_38242124__IMC__86_B8,13 | Lung | Primary cancer | 3,030 | Tumor/Malignant | 26.8% | 0.89 | 0.31 |
| NSCLC_38242124__IMC__86_B8,2 | Lung | Primary cancer | 662 | Other | 31.3% | 0.48 | 0.74 |
| NSCLC_38242124__IMC__86_B8,3 | Lung | Primary cancer | 1,463 | Stromal | 44.0% | 0.89 | 0.35 |
| NSCLC_38242124__IMC__86_B8,4 | Lung | Primary cancer | 1,564 | Tumor/Malignant | 41.0% | 0.91 | 0.26 |
| NSCLC_38242124__IMC__86_B8,5 | Lung | Primary cancer | 3,083 | Other | 27.6% | 0.41 | 0.93 |
| NSCLC_38242124__IMC__86_B8,6 | Lung | Primary cancer | 2,756 | Tumor/Malignant | 71.6% | 0.98 | 0.09 |
| NSCLC_38242124__IMC__86_B8,7 | Lung | Primary cancer | 2,854 | Other | 23.4% | 0.49 | 0.91 |
| NSCLC_38242124__IMC__86_B8,8 | Lung | Primary cancer | 2,988 | Tumor/Malignant | 35.2% | 0.96 | 0.12 |